Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

Esketamine in patient with treatment resistant depression: Outcome of the temporary authorization for use programme in France

Introduction Esketamine nasal spray has been developed for patients with treatment resistant depression. Objectives A cohort Temporary Authorization for Use (ATUc) allowed to collect for a 6-month period the first data in real life Methods On 02/08/2019 the French National Agency for Medicines...

Full description

Bibliographic Details
Main Authors:	E. Gaudre Wattinne, L. Mekaoui, M. Rothärmel, M.A. Codet, S. Bouju
Format:	Article
Language:	English
Published:	Cambridge University Press 2021-04-01
Series:	European Psychiatry
Subjects:	treatment resistant depression spray nasal glutamatergic pathway esketamine
Online Access:	https://www.cambridge.org/core/product/identifier/S0924933821018344/type/journal_article

Similar Items

ESKALE study, a French real-world study of esketamine nasal spray for patients with treatment-resistant depression
by: S. Ludovic, et al.
Published: (2022-06-01)

Esketamine versus placebo on time to remission in major depressive disorder with acute suicidality
by: Dong-Jing Fu, et al.
Published: (2023-08-01)

Management of treatment-resistant depression with esketamine nasal spray: clinical questions for daily practice in Gulf Cooperation Council countries
by: Nahida Nayaz Ahmed, et al.
Published: (2023-12-01)

Real-world approach to managing dysgeusia following the use of esketamine nasal spray: a case report
by: Nicholas A. Bossaller, et al.
Published: (2020-02-01)

The role of intranasal esketamine in treatment-resistant depression
by: A. Fraga, et al.
Published: (2021-04-01)

ICEBERG study: an indirect adjusted comparison estimating the long-term benefit of esketamine nasal spray when compared with routine treatment of treatment resistant depression in general psychiatry
by: Albino J. Oliveira-Maia, et al.
Published: (2023-10-01)

Clinical stability after compassionate use of intranasal esketamine in treatment-resistant depression
by: D. Hernandez Huerta, et al.
Published: (2022-06-01)

Indirect adjusted comparison of 6-month clinical outcomes between esketamine nasal spray and other real-world polypharmacy treatment strategies for treatment resistant depression: results from the ICEBERG study
by: Albino J. Oliveira-Maia, et al.
Published: (2023-10-01)

Esketamine and Psilocybin—The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review
by: Dominika Psiuk, et al.
Published: (2022-09-01)

A Meta-Analysis of the Antidepressant Responses in Pivotal Trials on Esketamine Nasal Spray and Atypical Antipsychotics
by: Wang L, et al.
Published: (2023-12-01)

Clinical efficacy and tolerability of Esketamine: a case series
by: C. Passani, et al.
Published: (2022-06-01)

How effective are ketamine or esketamine in treatment-resistant depression?
by: N. Veluri, et al.
Published: (2021-04-01)

Esketamine, a new treatment for resistant depression: a systematic review of the literature
by: Mercedes Valtueña García, et al.
Published: (2021-07-01)

Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study
by: Nagahide Takahashi, et al.
Published: (2021-10-01)

ESKALE study, a French real-world study describing TRD patients with Esketamine nasal spray: final analysis
by: L. Samalin, et al.
Published: (2023-03-01)

Impact of Repeated Doses of Subcutaneous Esketamine on Acute Dissociative Symptoms in Treatment-Resistant Depression
by: Lorena Catarina Del Sant, et al.
Published: (2022-12-01)

Heterogeneous trajectory of depressive symptoms after repeated subcutaneous esketamine injections
by: Matheus Ghossain Barbosa, et al.
Published: (2021-01-01)

Treating with esketamine nasal, will increase blood pressure?
by: V. Rosello-Molina, et al.
Published: (2021-04-01)

Case report: Intranasal esketamine for severe major depressive disorder with psychotic features
by: Maximilian Carter, et al.
Published: (2022-07-01)

Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder
by: S. Faisant, et al.
Published: (2022-06-01)

Montgomery‐Åsberg Depression Rating Scale factors in treatment‐resistant depression at onset of treatment: Derivation, replication, and change over time during treatment with esketamine
by: Stephane Borentain, et al.
Published: (2022-12-01)

Esketamine pretreatment during cesarean section reduced the incidence of postpartum depression: a randomized controlled trail
by: Shixia Xu, et al.
Published: (2024-01-01)

Use of intranasal esketamine in a girl with treatment-resistant depression and autism spectrum disorders
by: Miriam Olivola, et al.
Published: (2022-02-01)

Efficacy and Safety of Esketamine Combined with Antidepressants for Treatment-Resistant Depression: A Meta-Analysis
by: Liu P, et al.
Published: (2022-12-01)

Intranasal Esketamine + CBT: a 6 months follow-up of a resistant depression complicated case
by: V. Martiadis, et al.
Published: (2022-06-01)

Effect of Sleep Disturbance on Efficacy of Esketamine in Treatment-Resistant Depression: Findings from Randomized Controlled Trials
by: Borentain S, et al.
Published: (2021-11-01)

Effect of postoperative application of esketamine on postoperative depression and postoperative analgesia in patients undergoing pancreatoduodenectomy: a randomized controlled trial protocol
by: Kaili Yu, et al.
Published: (2023-08-01)

The cognitive effects of esketamine: what do we know so far?
by: M. Barbosa, et al.
Published: (2022-06-01)

Repeated, low-dose oral esketamine in patients with treatment-resistant depression: pilot study
by: Sanne Y. Smith-Apeldoorn, et al.
Published: (2022-01-01)

Short-term cognitive effects of repeated-dose esketamine in adolescents with major depressive disorder and suicidal ideation: a randomized controlled trial
by: Xiaofeng Lan, et al.
Published: (2023-09-01)

Effect of esketamine on postoperative depressive symptoms in patients undergoing thoracoscopic lung cancer surgery: A randomized controlled trial
by: Shu-lin Gan, et al.
Published: (2023-03-01)

The efficacy and safety of esketamine in the treatment of major depressive disorder with suicidal ideation: study protocol for a randomized controlled trial
by: Haiyan Liu, et al.
Published: (2022-11-01)

Efficacy and safety of ketamine and esketamine for unipolar and bipolar depression: an overview of systematic reviews with meta-analysis
by: Alessandro Rodolico, et al.
Published: (2024-02-01)

Repeated oral esketamine in patients with treatment resistant depression and comorbid posttraumatic stress disorder
by: J.K.E. Veraart, et al.
Published: (2023-05-01)

A comparison between patients who suffer from major depression and are treated with Esketamine – one group participates in group therapy and the other one does not
by: H. Yaniv, et al.
Published: (2022-06-01)

Repeated intravenous esketamine treatment in patients with ECT-resistant major depressive disorder
by: A. Safai Pour, et al.
Published: (2022-12-01)

Case report: Intramuscular ketamine or intranasal esketamine as a treatment in four patients with major depressive disorder and comorbid anorexia nervosa
by: Johanna Louise Keeler, et al.
Published: (2023-05-01)

Case report: Effectiveness of brexpiprazole and esketamine/ketamine combination: A novel therapeutic strategy in five cases of treatment-resistant depression
by: Lai Fong Chan, et al.
Published: (2022-07-01)

The Efficacy and Safety of Intranasal Formulations of Ketamine and Esketamine for the Treatment of Major Depressive Disorder: A Systematic Review
by: Ludivine Boudieu, et al.
Published: (2023-12-01)

Global Trends and Hotspots in Esketamine Research: A Bibliometric Analysis of Past and Estimation of Future Trends
by: Li X, et al.
Published: (2022-04-01)